Reduced risk for thrombosis using noble metal coated stents (NOBLE STENT)

Reference number
Coordinator Bactiguard AB
Funding from Vinnova SEK 1 480 000
Project duration September 2019 - August 2021
Status Ongoing
Venture Swelife and Medtech4Health - Collaborative Projects for Improved Health
Call Swelife and Medtech4Health - Collaborative Projects for Improved Health (Spring 2019)

Purpose and goal

One problem with the use of stents is that platelets in the blood adhere to the stents and form blood clots. To reduce this risk, the patient is given high doses of drugs that suppress platelet activation, which is often a clinical problem as it can cause complications. Coating the stents with Bactiguard´s coating is expected to reduce the activation of platelets and thus the tendency for clots to form. The goal is that patients with stents should thus have a reduced need for drugs with platelet inhibitors, thus mitigating the complications they cause.

Expected results and effects

In preliminary laboratory tests with human blood, Bactiguard has found that coating of stents reduces platelet activation as well as lower activation of white platelets, which reduces the risk of thrombosis, inflammation and blood clots. It has been seen that stents with Bactiguard coating cause less activation of ADP and TRAP receptors in the platelets. We expect to see a clear reduction in coagulation parameters in our ex vivo / in vitro experiments, in line with what the initial experiments have shown, in which case we proceed to in vivo in pigs where we also expect a reduction.

Planned approach and implementation

This project is divided into 3 WP. WP 1 is focused coating developement and on removing and re-installing the stent in the delivery catheter In WP 2, ex vivo / in vitro experiments on coated and uncoated stents are performed for both human blood and pig blood. Several different coagulation parameters will be measured, mainly platelet activation. In WP3, coated and uncoated stents will be evaluated in vivo in a pig model at KI. Analyzes are done with angiography in vivo, biochemical analyzes and post-mortem analyzes of stent and vessels.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 15 May 2019

Reference number 2019-01472

Page statistics